Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

arGEN-X introduces NHance technology to create therapeutic antibodies

arGEN-X announces today the launch of NHance, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

19 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

12 Mar 2012

Ultragenyx completes UX001 Phase 1 study on hereditary inclusion body myopathy

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed.

9 Mar 2012

Enrollment complete in Palatin's bremelanotide Phase 2B trial for FSD

Palatin Technologies, Inc. today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction.

9 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Zalicus fourth quarter revenue decreases to $8.2 million

Zalicus Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.

8 Mar 2012

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

Certara acquires Simcyp

Simcyp Limited announces its acquisition by Certara, a leading provider of drug discovery and development software and scientific consulting services.

24 Feb 2012

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin.

16 Feb 2012

UC Cancer Institute to enroll up to 60 patients for AMG 595 phase-1 trial

The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

16 Feb 2012

Trevena commences TRV130 Phase I clinical trial for severe post-operative pain

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.

13 Feb 2012

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B.

3 Feb 2012